Health Care · Pharmaceutical Preparations

LYEL Lyell Immunopharma Inc SEC Filings & Insider Trading Activity 2026

company
CIK 180695279 filings

LYEL at a glance

Lyell Immunopharma Inc (LYEL, SEC CIK 1806952) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Lyell Immunopharma Inc (LYEL) reported revenue of $36,000 (down 41.0% from FY2024) and a net loss of $274.4 million. Diluted EPS was -$16.06.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Lyell Immunopharma Inc (LYEL) shares worth $34.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Lee Gary K. on November 10, 2026 of 129 shares at $15.93 per share.
  • In the last 90 days, LYEL insiders reported 2 open-market purchases ($50.0M) and 6 open-market sales ($29K) on Form 4, a net purchase of $50.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$36K
−41.0% vs prior year
Insiders · 90 days
2 buys · 6 sells
Net +$50.0M
13F holders
22 funds
$34.8M · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added trade-policy risk: April 2026 tariffs up to 100% on certain imported pharmaceuticals, APIs and key starting materials
  • Most materially updated capital risk: November 2026 Securities Purchase Agreement is the only committed external funding source
  • Regulatory compliance risk: cGMP or cGTP failures could trigger clinical holds, production suspension, recalls or approval withdrawal
  • Near-term trial risk: Competitor liso-cel and axi-cel availability may reduce enrollment in the PiNACLE-H2H trial
  • Financial dilution risk: ICT may receive up to 1.85 million additional shares, including 1.1 million issued in July 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved products or product sales
  • Operating loss $48.3M vs $37.3M YoY, net loss $45.5M vs $38.8M
  • R&D expense $40.9M vs $28.2M, driven by increased clinical trial activity
  • Cash, equivalents and marketable securities $194.0M; operating cash outflow $107.0M
  • Guidance: liquidity sufficient for at least 12 months; additional capital needed, with clinical and manufacturing costs rising

AI summary of the LYEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • Ronde-cel efficacy remained strong: 91% overall response and 77% complete response among 44 evaluable 3L+ patients
  • Durability signals favorable, with complete response rates estimated at 92% at six months and 75% at 12 months
Filed Nov 4, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • $80.0 million gross proceeds targeted through private placement of 7,428,040 common shares
  • $10.77 per-share issuance price, implying potential dilution for existing shareholders
Filed Sep 10, 2026Full analysis →

Item 8.01: Other Events

  • LYL273 technology transfer completed at Lyell’s LyFE Manufacturing Facility in Bothell, Washington
  • Phase 1/2 trial timeline updated for metastatic colorectal cancer

Item EX-99.1: Item EX-99.1

  • LyFE manufacturing transfer completed after FDA review, advancing LYL273 toward scalable clinical supply
  • Improved manufacturing process and analytical methods target higher performance and capacity

AI summaries of LYEL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LYEL

Don't miss the next LYEL filing

  • Alerts as it files. A push when LYEL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LYEL, by share count.
  • Ask anything. An AI agent that reads every LYEL filing and answers with sources.

LYEL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lee Gary K.SellNov 10, 2026$15.93
Bulis Veronica SanchezSellNov 10, 2026$15.93
Seely LynnSellNov 10, 2026$15.93
Hill Stephen J.SellNov 10, 2026$15.93
ARCH Venture Partners IX, LLCBuyNov 4, 2026$10.77
ARCH Venture Fund XIII, L.P.BuyNov 4, 2026$10.77
Aguirre Jarrad MattieuSellOct 12, 2026$8.63
Aguirre Jarrad MattieuASep 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$130K$61K$36K
Operating Income--$358.8M-$269.4M
Net Income-$234.6M-$343.0M-$274.4M
Op. Margin--588123.0%-748344.4%
Net Margin-180486.2%-562285.2%-762355.6%
Balance Sheet
Total Assets-$490.9M$340.1M
Equity-$382.8M$248.2M
ROE--89.6%-110.6%
Per Share
EPS$-0.93$-1.31$-16.06
Cash Flow
Operating CF--$162.4M-$150.0M
CapEx$2.7M$464K$780K

Source: XBRL data in Lyell Immunopharma Inc (LYEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LYEL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LYEL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$34.8M
Q2 202622$43.0M
Q1 202620$51.6M
Q4 202521$66.7M
Q3 202517$32.4M
Q2 202520$15.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LYEL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
8-KNov 4, 2026Analysis-
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 13, 2026--
4Sep 10, 2026--
8-KSep 10, 2026Analysis-
4Sep 10, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
10-QAug 6, 2026-
8-KAug 6, 2026Analysis-
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 20, 2026--

Related Health Care companies

All Health Care →

LYEL SEC filings: frequently asked questions

Are LYEL insiders buying or selling?

In the last 90 days, Lyell Immunopharma Inc (LYEL) officers, directors and 10% owners reported 2 open-market purchases worth $50.0 million by 2 insiders and 6 open-market sales worth $28,757 by 6 insiders on Form 4, a net purchase of $50.0 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LYEL stock?

As of September 30, 2026, the largest Lyell Immunopharma Inc (LYEL) holders among the 13F filers tracked by SignalX were BlackRock ($7.8 million), Vanguard Capital Management LLC ($7.3 million), AQR Capital Management ($3.4 million), Alphabet Inc ($2.9 million), State Street Corp ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LYEL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Lyell Immunopharma Inc (LYEL) reported revenue of $36,000 (down 41.0% from FY2024) and a net loss of $274.4 million. Diluted EPS was -$16.06. The figures come from the XBRL data in the 10-K.

What did LYEL report in its latest 8-K?

Lyell Immunopharma Inc (LYEL) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest LYEL SEC filings?

Lyell Immunopharma Inc (LYEL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.

What is LYEL's SEC CIK number?

Lyell Immunopharma Inc (LYEL)'s SEC Central Index Key (CIK) is 1806952. EDGAR lists every LYEL filing under that number.

Ask anything about LYEL

The research agent reads LYEL's filings, financials, insider trades and 13F holders, then answers with sources.